---
document_datetime: 2025-12-02 06:13:42
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/beqvez.html
document_name: beqvez.html
version: success
processing_time: 0.1105686
conversion_datetime: 2025-12-26 19:25:37.65729
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Beqvez (previously Durveqtix)

[RSS](/en/individual-human-medicine.xml/243388)

##### Withdrawn

This medicine's authorisation has been withdrawn

fidanacogene elaparvovec Medicine Human Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Beqvez (previously Durveqtix)](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 15 May 2025, the European Commission withdrew the marketing authorisation for Beqvez (fidanacogene elaparvovec) in the European Union (EU). The withdrawal was requested by the marketing authorisation holder, Pfizer Europe MA EEIG, due to commercial reasons.

Beqvez was granted conditional marketing authorisation in the EU on 24 July 2024 for the treatment of severe and moderately severe haemophilia B. The product had not been marketed in the EU.

Durveqtix : EPAR - Medicine overview

Reference Number: EMA/331501/2024

English (EN) (212.12 KB - PDF)

**First published:** 01/08/2024

**Last updated:** 04/06/2025

[View](/en/documents/overview/durveqtix-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-249)

български (BG) (282.76 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/bg/documents/overview/durveqtix-epar-medicine-overview_bg.pdf)

español (ES) (213.38 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/es/documents/overview/durveqtix-epar-medicine-overview_es.pdf)

čeština (CS) (259.36 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/cs/documents/overview/durveqtix-epar-medicine-overview_cs.pdf)

dansk (DA) (209.27 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/da/documents/overview/durveqtix-epar-medicine-overview_da.pdf)

Deutsch (DE) (221.22 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/de/documents/overview/durveqtix-epar-medicine-overview_de.pdf)

eesti keel (ET) (201.73 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/et/documents/overview/durveqtix-epar-medicine-overview_et.pdf)

ελληνικά (EL) (294 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/el/documents/overview/durveqtix-epar-medicine-overview_el.pdf)

français (FR) (216.98 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/fr/documents/overview/durveqtix-epar-medicine-overview_fr.pdf)

hrvatski (HR) (251.79 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/hr/documents/overview/durveqtix-epar-medicine-overview_hr.pdf)

italiano (IT) (210.53 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/it/documents/overview/durveqtix-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (268.75 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/lv/documents/overview/durveqtix-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (255.3 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/lt/documents/overview/durveqtix-epar-medicine-overview_lt.pdf)

magyar (HU) (247.5 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/hu/documents/overview/durveqtix-epar-medicine-overview_hu.pdf)

Malti (MT) (266.55 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/mt/documents/overview/durveqtix-epar-medicine-overview_mt.pdf)

Nederlands (NL) (218.02 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/nl/documents/overview/durveqtix-epar-medicine-overview_nl.pdf)

polski (PL) (256.58 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/pl/documents/overview/durveqtix-epar-medicine-overview_pl.pdf)

português (PT) (215.5 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/pt/documents/overview/durveqtix-epar-medicine-overview_pt.pdf)

română (RO) (259.85 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/ro/documents/overview/durveqtix-epar-medicine-overview_ro.pdf)

slovenčina (SK) (252.05 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/sk/documents/overview/durveqtix-epar-medicine-overview_sk.pdf)

slovenščina (SL) (243.88 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/sl/documents/overview/durveqtix-epar-medicine-overview_sl.pdf)

Suomi (FI) (204.37 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/fi/documents/overview/durveqtix-epar-medicine-overview_fi.pdf)

svenska (SV) (209.3 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/sv/documents/overview/durveqtix-epar-medicine-overview_sv.pdf)

Durveqtix : EPAR - Risk management plan

English (EN) (3.18 MB - PDF)

**First published:** 01/08/2024

**Last updated:** 04/06/2025

[View](/en/documents/rmp/durveqtix-epar-risk-management-plan_en.pdf)

## Product information

Beqvez : EPAR - Product information

English (EN) (2.35 MB - PDF)

**First published:** 01/08/2024

**Last updated:** 04/06/2025

[View](/en/documents/product-information/beqvez-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-946)

български (BG) (1.37 MB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/bg/documents/product-information/beqvez-epar-product-information_bg.pdf)

español (ES) (1.27 MB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/es/documents/product-information/beqvez-epar-product-information_es.pdf)

čeština (CS) (1.33 MB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/cs/documents/product-information/beqvez-epar-product-information_cs.pdf)

dansk (DA) (1.29 MB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/da/documents/product-information/beqvez-epar-product-information_da.pdf)

Deutsch (DE) (1.33 MB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/de/documents/product-information/beqvez-epar-product-information_de.pdf)

eesti keel (ET) (1.3 MB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/et/documents/product-information/beqvez-epar-product-information_et.pdf)

ελληνικά (EL) (1.35 MB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/el/documents/product-information/beqvez-epar-product-information_el.pdf)

français (FR) (1.3 MB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/fr/documents/product-information/beqvez-epar-product-information_fr.pdf)

hrvatski (HR) (1.33 MB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/hr/documents/product-information/beqvez-epar-product-information_hr.pdf)

íslenska (IS) (1.22 MB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/is/documents/product-information/beqvez-epar-product-information_is.pdf)

italiano (IT) (1.25 MB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/it/documents/product-information/beqvez-epar-product-information_it.pdf)

latviešu valoda (LV) (1.24 MB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/lv/documents/product-information/beqvez-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.21 MB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/lt/documents/product-information/beqvez-epar-product-information_lt.pdf)

magyar (HU) (1.35 MB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/hu/documents/product-information/beqvez-epar-product-information_hu.pdf)

Malti (MT) (1.67 MB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/mt/documents/product-information/beqvez-epar-product-information_mt.pdf)

Nederlands (NL) (1.32 MB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/nl/documents/product-information/beqvez-epar-product-information_nl.pdf)

norsk (NO) (1.26 MB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/no/documents/product-information/beqvez-epar-product-information_no.pdf)

polski (PL) (1.41 MB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/pl/documents/product-information/beqvez-epar-product-information_pl.pdf)

português (PT) (1.24 MB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/pt/documents/product-information/beqvez-epar-product-information_pt.pdf)

română (RO) (1.35 MB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/ro/documents/product-information/beqvez-epar-product-information_ro.pdf)

slovenčina (SK) (1.41 MB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/sk/documents/product-information/beqvez-epar-product-information_sk.pdf)

slovenščina (SL) (1.25 MB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/sl/documents/product-information/beqvez-epar-product-information_sl.pdf)

Suomi (FI) (1.33 MB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/fi/documents/product-information/beqvez-epar-product-information_fi.pdf)

svenska (SV) (1.22 MB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/sv/documents/product-information/beqvez-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IAIN/0001 24/09/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Beqvez : EPAR - All authorised presentations

English (EN) (60.5 KB - PDF)

**First published:** 01/08/2024

**Last updated:** 04/06/2025

[View](/en/documents/all-authorised-presentations/beqvez-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-129)

български (BG) (65.47 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/bg/documents/all-authorised-presentations/beqvez-epar-all-authorised-presentations_bg.pdf)

español (ES) (63.83 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/es/documents/all-authorised-presentations/beqvez-epar-all-authorised-presentations_es.pdf)

čeština (CS) (57.94 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/cs/documents/all-authorised-presentations/beqvez-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (61.04 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/da/documents/all-authorised-presentations/beqvez-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (61.17 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/de/documents/all-authorised-presentations/beqvez-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (58.57 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/et/documents/all-authorised-presentations/beqvez-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (65.41 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/el/documents/all-authorised-presentations/beqvez-epar-all-authorised-presentations_el.pdf)

français (FR) (58.67 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/fr/documents/all-authorised-presentations/beqvez-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (58.98 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/hr/documents/all-authorised-presentations/beqvez-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (59.81 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/is/documents/all-authorised-presentations/beqvez-epar-all-authorised-presentations_is.pdf)

italiano (IT) (56.83 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/it/documents/all-authorised-presentations/beqvez-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (60.11 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/lv/documents/all-authorised-presentations/beqvez-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (61.27 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/lt/documents/all-authorised-presentations/beqvez-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (58.74 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/hu/documents/all-authorised-presentations/beqvez-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (62.91 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/mt/documents/all-authorised-presentations/beqvez-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (57.86 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/nl/documents/all-authorised-presentations/beqvez-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (60.06 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/no/documents/all-authorised-presentations/beqvez-epar-all-authorised-presentations_no.pdf)

polski (PL) (63.12 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/pl/documents/all-authorised-presentations/beqvez-epar-all-authorised-presentations_pl.pdf)

português (PT) (59.98 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/pt/documents/all-authorised-presentations/beqvez-epar-all-authorised-presentations_pt.pdf)

română (RO) (59.47 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/ro/documents/all-authorised-presentations/beqvez-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (59.4 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/sk/documents/all-authorised-presentations/beqvez-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (57.42 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/sl/documents/all-authorised-presentations/beqvez-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (56.88 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/fi/documents/all-authorised-presentations/beqvez-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (58.58 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

04/06/2025

[View](/sv/documents/all-authorised-presentations/beqvez-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Beqvez (previously Durveqtix) Active substance fidanacogene elaparvovec International non-proprietary name (INN) or common name fidanacogene elaparvovec Therapeutic area (MeSH) Hemophilia B

### Pharmacotherapeutic group

Antihemorrhagics

## Authorisation details

EMA product number EMEA/H/C/004774

Advanced therapy

This medicine is classified as an advanced therapy medicinal product (ATMP): a medicine for human use that is based on genes, tissues or cells. It offers groundbreaking new opportunities for the treatment of disease and injury. For more information, see [Advanced therapy medicinal products: Overview](/node/69659) .

Conditional approval

This medicine received a conditional marketing authorisation. This was granted in the interest of public health because the medicine addresses an unmet medical need and the benefit of immediate availability outweighs the risk from less comprehensive data than normally required. For more information, see [Conditional marketing authorisation](/node/68774) .

PRIME: priority medicine

This medicine was granted entry to the EMA Priority Medicines (PRIME) scheme during its development. PRIME is a scheme launched by EMA to enhance support for the development of medicines that target an unmet medical need. This voluntary scheme is based on enhanced interaction and early dialogue with developers of promising medicines, to optimise development plans and speed up evaluation so these medicines can reach patients earlier. For more information, see [PRIME: priority medicines](/node/69853) .

Marketing authorisation holder

Pfizer Europe MA EEIG

Boulevard de la Plaine 17

Opinion adopted 30/05/2024 Marketing authorisation issued 24/07/2024 Withdrawal of marketing authorisation 15/05/2025 Revision 3

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Beqvez : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (178.67 KB - PDF)

**First published:** 20/05/2025

**Last updated:** 04/06/2025

[View](/en/documents/procedural-steps-after/beqvez-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Beqvez : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (160.36 KB - PDF)

**First published:** 23/10/2024

**Last updated:** 04/06/2025

[View](/en/documents/procedural-steps-after/beqvez-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Durveqtix : EPAR - Public assessment report

Adopted

Reference Number: EMA/323453/2024

English (EN) (5.65 MB - PDF)

**First published:** 01/08/2024

**Last updated:** 04/06/2025

[View](/en/documents/assessment-report/durveqtix-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Durveqtix

Reference Number: EMA/CHMP/232716/2024

English (EN) (224.27 KB - PDF)

**First published:** 31/05/2024

**Last updated:** 04/06/2025

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-durveqtix_en.pdf)

#### News on Beqvez (previously Durveqtix)

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 May 2024](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-30-may-2024) 31/05/2024

[New gene therapy treatment for haemophilia B](/en/news/new-gene-therapy-treatment-haemophilia-b) 31/05/2024

**This page was last updated on** 04/06/2025

## Share this page

[Back to top](#main-content)